# A Study to Learn How the Study Treatment BAY2395840 Moves Into, Through and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Moderate Reduced Kidney Function and in Healthy Male and Female Participants With Normal Kidney Function

> **NCT05406219** · PHASE1 · WITHDRAWN · sponsor: **Bayer**

## Conditions studied

- Diabetic Neuropathic Pain
- Renal Impairment
- Healthy Volunteers

## Interventions

- **DRUG:** BAY2395840

## Key facts

- **NCT ID:** NCT05406219
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-05-15
- **Primary completion:** 2023-08-17
- **Final completion:** 2023-10-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Discontinuation of program.
- **Last updated:** 2023-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05406219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05406219, "A Study to Learn How the Study Treatment BAY2395840 Moves Into, Through and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Moderate Reduced Kidney Function and in Healthy Male and Female Participants With Normal Kidney Function". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05406219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*